Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal
E A Ranheim, T J Kipps, E A Ranheim, T J Kipps
Abstract
Cognate interactions between antigen-presenting B and T cells play crucial roles in immunologic responses. T cells that have been activated via the crosslinking of CD3 are able to induce B cell proliferation and immunoglobulin secretion in a major histocompatibility complex-unrestricted and contact-dependent manner. We find that such activated human CD4+ T cells, but not control Ig-treated T cells, may induce normal or leukemic B cells to express B7/BB1 and significantly higher levels of CD54 intercellular adhesion molecule 1 via a process that also requires direct cell-cell contact. To discern what cell surface molecule(s) may be responsible for signalling B cells to express B7/BB1, we added various monoclonal antibodies (mAbs) specific for T or B cell accessory molecules or control mAbs to cocultures of alpha-CD3-activated T cells and resting B cells. We find that only alpha-CD40 mAbs can significantly inhibit the increased expression of B7/BB1, suggesting that the ligand for CD40 expressed on activated T cells may be an important inducer of B7/BB1 expression. Subsequent experiments in fact demonstrate that alpha-CD40 mAbs, but not control mAbs, induce changes in B cell phenotype similar to those induced by activated T cells when the mAbs are presented on Fc gamma RII (CDw32)-expressing L cells. These phenotypic changes have significant effects on B cell function. Whereas chronic lymphocytic leukemia (CLL) B cells normally are very poor stimulators in allogeneic mixed lymphocyte reactions (MLRs), CLL-B cells preactivated via CD40 crosslinking are significantly better presenters of alloantigen, affecting up to 30-fold-greater stimulation of T cell proliferation than that induced by control treated or nontreated CLL-B cells. Similarly, the MLR of T cells stimulated by allogeneic nonleukemic B cells can be enhanced significantly if the stimulator B cells are preactivated via CD40 crosslinking. The enhanced MLR generated by such preactivated B cells may be inhibited by blocking B7/BB1-CD28 interaction with CTLA4Ig. These studies demonstrate a novel, CD40-dependent pathway for inducing B cell expression of B7/BB1 and enhancing B cell antigen-presenting cell activity that can be initiated via cell-cell contact with alpha-CD3-stimulated CD4+ T cells.
References
- Proc Natl Acad Sci U S A. 1990 Oct;87(19):7698-702
- J Immunol. 1990 Oct 1;145(7):2025-34
- J Immunol. 1990 Dec 15;145(12):4018-25
- Cell Immunol. 1991 Mar;133(1):206-18
- J Immunol. 1991 Feb 15;146(4):1118-24
- J Exp Med. 1991 Mar 1;173(3):705-10
- J Exp Med. 1991 Mar 1;173(3):721-30
- J Exp Med. 1991 Mar 1;173(3):759-62
- J Immunol. 1991 Mar 15;146(6):1722-9
- J Immunol. 1991 Apr 15;146(8):2544-52
- J Exp Med. 1991 Jun 1;173(6):1433-9
- J Exp Med. 1992 Jan 1;175(1):131-8
- J Exp Med. 1979 Aug 1;150(2):246-55
- Clin Immunol Immunopathol. 1979 Sep;14(1):77-85
- Blood. 1982 Nov;60(5):1075-81
- J Exp Med. 1984 Dec 1;160(6):1717-35
- J Immunol. 1985 Apr;134(4):2269-75
- Nature. 1985 Apr 11-17;314(6011):537-9
- Science. 1985 Aug 2;229(4712):475-9
- J Immunol. 1985 Sep;135(3):1661-7
- J Exp Med. 1985 Sep 1;162(3):962-78
- Proc Natl Acad Sci U S A. 1986 Jun;83(12):4494-8
- J Immunol. 1986 Oct 15;137(8):2395-404
- J Immunol. 1987 Feb 15;138(4):1051-5
- J Immunol. 1987 Mar 15;138(6):1667-73
- J Immunol. 1987 May 1;138(9):2848-56
- Blood. 1987 Aug;70(2):418-27
- J Immunol. 1987 Nov 15;139(10):3260-7
- J Exp Med. 1992 Feb 1;175(2):353-60
- J Immunol. 1992 Apr 1;148(7):1985-92
- Nature. 1992 Apr 16;356(6370):607-9
- Blood. 1992 May 15;79(10):2688-93
- Clin Lab Med. 1992 Jun;12(2):237-75
- Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6550-4
- J Clin Invest. 1992 Jul;90(1):229-37
- J Immunol. 1992 Aug 1;149(3):775-82
- J Immunol. 1992 Aug 1;149(3):789-95
- Science. 1992 Aug 7;257(5071):792-5
- Cell Immunol. 1991 Jan;132(1):45-55
- J Exp Med. 1991 Sep 1;174(3):561-9
- J Immunol. 1992 Jan 15;148(2):404-10
- J Immunol. 1988 Mar 1;140(5):1477-84
- Clin Lab Med. 1988 Mar;8(1):163-77
- J Immunol. 1988 Jun 1;140(11):3736-44
- J Immunol. 1988 Jun 1;140(11):3773-8
- Blood. 1988 Oct;72(4):1431-4
- J Immunol. 1988 Oct 1;141(7):2230-9
- J Exp Med. 1989 Jan 1;169(1):239-54
- J Immunol. 1989 Sep 15;143(6):1807-14
- J Immunol. 1989 Oct 15;143(8):2714-22
- Adv Immunol. 1989;47:117-85
- J Immunol. 1989 Dec 15;143(12):3873-80
- Science. 1990 Mar 30;247(4950):1584-7
- Science. 1990 Jun 15;248(4961):1349-56
- Nature. 1990 Aug 2;346(6283):425-34
- Ann Intern Med. 1990 Oct 1;113(7):525-39
- Proc Natl Acad Sci U S A. 1990 Oct;87(19):7722-6
Source: PubMed